Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease

Patent metadata

Field	Value
Publication number	US-2017143763-A1
Application number	US-201715426367-A
Country	US
Kind code	A1
Filing date	Feb 7, 2017
Priority date	Feb 22, 2013
Publication date	May 25, 2017
Grant date	—

Abstract

An object of the present invention is to provide an orally administered adsorbent capable of adsorbing large quantities of tryptophan or indoxyl sulfate in the presence of bile acid. Accordingly, the above object can be solved by an orally administered adsorbent characterized by containing surface-modified spherical activated carbon having bulk density from 0.30 g/mL to 0.46 g/mL, a specific surface area determined by the Brunauer-Emmett-Teller (BET) method of not less than 1900 m 2 /g, total acidic group content from 0.30 meq/g to 1.20 meq/g, and total basic group content from 0.20 meq/g to 0.9 meq/g.

First claim

1 . A method for preventing and treating disease related to indoxyl sulfate using surface-modified spherical activated carbon,
the surface-modified spherical activated carbon having bulk density from 0.30 g/mL to 0.46 g/mL, a specific surface area determined by the Brunauer-Emmeett-Teller method (BET) of not less than 1900 m 2 /g, total acidic group content from 0.30 meq/g to 1.20 meq/g, and the total basic group content from 0.20 meq/g to 0.9 meq/g.

2 . A method for adsorbing indoxyl sulfate using surface-modified spherical activated carbon, the surface-modified spherical activated carbon having bulk density from 0.30 g/mL to 0.46 g/mL, a specific surface area determined by the Brunauer-Emmeett-Teller method (BET) of not less than 1900 m 2 /g, total acidic group content from 0.30 meq/g to 1.20 meq/g, and the total basic group content from 0.20 meq/g to 0.9 meq/g,
the adsorption being performed in the presence of a high concentration of bile acid.

Assignees

• Kureha Corp

Inventors

• Sonobe Naohiro
• Wakahoi Takashi
• Akita Takahiro

Classifications

• A61P39/02

  Antidotes · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• B01J20/28004

  Sorbent size or size distribution, e.g. particle size · CPC title

• B01J20/28066

  being more than 1000 m2/g · CPC title